SpectronRx, an Indiana-based radiopharmaceutical CDMO and isotope producer, has raised $85 million in financing led by OrbiMed. The company provides end-to-end services including radiolabeling of monoclonal antibodies, peptides, and molecules with therapeutic isotopes like Ac-225, Lu-177, and I-131, plus GMP manufacturing, global procurement, logistics, and regulatory support for cancer therapies. The capital will expand isotope production and CDMO/CMO capabilities at its Grissom Aeroplex campus in Bunker Hill.
Radiopharma CDMO Investments Surge
The round arrives amid rising capital in radiopharmaceutical manufacturing. Nucleus RadioPharma raised $72M, while Evergreen Theragnostics secured $76M before its $250M acquisition by Lantheus. NorthStar Medical Radioisotopes has drawn over $190M in grants and private funding. SpectronRx's focus on integrated isotope production and logistics targets supply chain gaps in theranostics.
Isotope Shortages Stall Theranostics
Radiopharmaceutical developers face chronic shortages of key isotopes like Ac-225, critical for targeted alpha therapies in prostate cancer and neuroblastoma. Current fragmented supply chains cause handoffs, delays, and risks in decay-sensitive logistics. Innovation accelerates, but reliable domestic production lags, constraining clinical and commercial scaling, per industry coverage.
End-to-End Platform Solves Fragmentation
SpectronRx offers radiolabeling, GMP contract manufacturing, and proprietary isotope production under one roof, including commercial-scale high-purity Ac-225 via accelerator-based methods. This eliminates multi-vendor risks, with global logistics and cold chain for short half-life isotopes. The Grissom campus spans 34 acres with over 200,000 sq ft of GMP space, scalable to 1M sq ft. Unlike developer-focused peers, SpectronRx serves as a pure-play CDMO for biotechs advancing oncology pipelines.
As John Zehner, CEO, noted:
"Radiopharmaceutical innovation is advancing rapidly, but isotope supply… remain critical constraints."
OrbiMed Bets on Supply Infrastructure
OrbiMed's investment signals conviction in domestic radiopharma infrastructure amid global supply vulnerabilities. The firm backs SpectronRx's expansion of clean rooms, hot cells, and cyclotrons at its strategically located Grissom Aeroplex, near an airport and within 12-hour drive to 60% of the U.S. population. This positions the company to handle surging demand for theranostics from Phase 1 to commercialization, according to local reporting.
$8B Market Fuels Alpha-Emitter Race
The radiopharmaceutical CDMO market stands at $8B with a 12.5% CAGR, driven by theranostics and personalized oncology. RadioMedix, a hybrid developer-manufacturer, raised $40M. NorthStar focuses on diagnostics like Tc-99m, while SpectronRx emphasizes therapeutic alpha-emitters. Recent approvals like Pluvicto highlight demand, but supply bottlenecks persist.
Repeat Founders Drive Cyclotron Expertise
Co-founders John Zehner and Anwer Rizvi bring 25-35 years each, having co-founded Eastern Isotopes, acquired by IBA, and led 50+ global cyclotron installations. Zehner steered Zevacor Molecular pre-Curium acquisition, earning Purdue's Distinguished Alumni award. COO Peter Webner adds GE Healthcare oncology experience. This serial expertise underpins FDA/EMA-inspected facilities producing approved drugs like FDG.
Campus Expansion Targets 12 Cyclotrons
With the financing, SpectronRx plans cyclotron scaling to 12 units, a 14-acre acquisition for 150k sq ft facility, and up to 100 new jobs in engineering, QA, and manufacturing over two years. Commercial Ac-225 production launched in late 2025 supports TAT programs. Partnerships with Bicycle Therapeutics and ARTBIO validate the platform amid hiring for 15+ roles.